Sequent Scientific Quarterly Results for Trading Insights
In Sept 2025, Sequent Scientific (SEQUENT) reported revenue ₹426 Cr and net profit ₹20 Cr — revenue +14.2% YoY. Also explore SEQUENT price trends to track price trends across different timeframes.
SEQUENT Quarterly Results — Revenue, Profit & EPS Highlights
Sequent Scientific latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with SEQUENT fair value to assess whether the stock is under or overvalued.
- Revenue of ₹426 Cr in Sept 2025 (+5.7% vs Mar 2025, +14.2% vs Sept 2024)
- Net Profit of ₹20 Cr in Sept 2025 (+100.0% vs Mar 2025, +233.3% vs Sept 2024)
- EBITDA of ₹56 Cr in Sept 2025 (+16.7% vs Mar 2025)
- Operating Margin of 13.0% in Sept 2025 (+2.0pp vs Mar 2025)
- Earnings Per Share of ₹0.59 in Sept 2025 (+59.5% vs Mar 2025)
Sequent Scientific Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SEQUENT quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 426 | 403 | 445 | 373 | 365 | 5.7% | 14.2% |
| Net Profit (₹ Cr) | 20 | 10 | 18 | 6 | 1 | - | - |
| EBITDA (₹ Cr) | 56 | 48 | 55 | 39 | 32 | - | - |
| EPS (₹) | 0.59 | 0.37 | 0.57 | 0.11 | -0.04 | - | - |
| Operating Margin (%) | 13.0% | 11.0% | 12.0% | 9.0% | 8.0% | - | - |
SEQUENT Share Price Trend — 1-Year Movement Across Quarterly Results
Sequent Scientific 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SEQUENT screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SEQUENT vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sequent Scientific latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores